Researchers at the University of Exeter are making significant progress in the development of a new prostate cancer drug, which could save the NHS millions of pounds and help thousands of patients.
The drug, which is still in the clinical trial phase, has shown promising results in reducing symptoms and slowing the progression of the disease.
According to the researchers, the new drug could potentially replace existing treatments, which are often expensive and have significant side effects.
The NHS could save millions of pounds by reducing hospital admissions and treatment costs, as well as alleviating the financial burden on patients who currently have to pay for expensive treatments out of pocket.
The researchers believe that the new drug could be available on the NHS within the next few years, subject to further clinical trials and regulatory approval.
Prostate cancer is one of the most common cancers in men in the UK, with over 56,000 new cases diagnosed each year. Existing treatments can be expensive and have significant side effects, making the new drug a promising development for patients.